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OBJECTIVES The aim of this study was to determine whether airport metal detector gates (AMDGs)
interfere with pacemakers (PMs) or implantable cardioverter-defibrillators (ICDs).
BACKGROUND It is currently unknown whether AMDGs interfere with implanted PMs or ICDs.
METHODS A total of 348 consecutive patients (200 PM and 148 ICD recipients) have been tested for
the occurrence of electromagnetic interference (EMI) within the electromagnetic field of a
worldwide-used airport metal detector.
RESULTS No interference, such as pacing or sensing abnormalities, was observed in any of the 200 PM
and 148 ICD patients; also no reprogramming occurred.
CONCLUSIONS In vivo testing of PM and ICD systems showed no EMI with a standard AMDG. Clinically
relevant interactions with implanted PMs or ICDs seem unlikely. (J Am Coll Cardiol 2003;
41:2054–9) © 2003 by the American College of Cardiology Foundation
Electromagnetic interference (EMI) with implanted pace-
makers (PMs) and implantable cardioverter-defibrillators
(ICDs) has been reported under various circumstances in
patients’ daily life (1–9). Thus, EMI should be considered as
a serious hazard for PM and ICD recipients.
The risk of EMI depends on several factors such as: 1)
the distance of the PM/ICD from the potential source of
EMI; 2) the oscillation frequency and field strength of the
disturbing electromagnetic field as parameters for induced
voltage; and 3) device-dependent technical details such as
PM sensitivity or unipolar or bipolar lead configuration.
Atrial oversensing due to detection of electric distur-
bances may result in a sudden increase of the ventricular
pacing rate or inappropriate mode switching to VDI or
DDI mode. Oversensing in the ventricular channel will
cause an inhibition of ventricular pacing and may result in
bradycardia-associated symptoms such as dizziness or even
syncope. In patients with an ICD, EMI may lead to false
arrhythmia detection and may cause inappropriate anti-
tachycardia pacing or internal shock delivery.
For the purpose of metal detection, one or several coils
are incorporated in airport metal detector gates (AMDGs).
Using alternating current, a primary magnetic flux is pro-
duced within the coil. Movement of a metal object within
these coils will induce a secondary magnetic flux, which
produces voltage changes in the coils that can be used for
metal detection.
STUDY OBJECTIVES
It is unknown whether the primary magnetic flux generated
by the AMDG interferes with current PM or ICD systems.
At a time of increasing security requirements, we evaluated
the influence of the AMDG on ICDs and permanent PMs
in vivo in a large series of patients.
METHODS
The study comprised 348 consecutive patients presenting
for routine follow-up of their PM or ICD devices at the
outpatient clinic of our institution. During routine check-
up, the correct PM/ICD function was tested by performing
a standardized follow-up protocol, including interrogation
of the device, arrhythmia diagnosis, atrial and ventricular
sensing, and pacing threshold tests, and exclusion of sensing
failures or oversensing by isometric contraction of the
pectoral and/or abdominal muscles. Any atrial or ventricular
sensing abnormality that could not be avoided by repro-
gramming of device parameters led to exclusion from the
study. Informed consent was obtained from all patients
before testing for interference with the AMDG.
A standard AMDG security gate (model 02PN10,
C.E.I.A., Viciomaggio, Italy) was used. The AMDGs
constructed in the same way are presently used in the
majority of airports in the U.S., Canada, and Europe.
Electromagnetic flux density, oscillation frequency, and
detection sensitivity were programmed according to the
current standard for international airports. The electromag-
netic field of the AMDG used is characterized by three peak
levels with pulse rates of 3.73, 4.98, and 5.98 kHz and
reaches a maximal electromagnetic flux density of 42 T.
Test protocol for implanted PMs. The basic rate and/or
atrioventricular delay were adjusted for the testing, with the
aim of permanent ventricular pacing. This was achieved by
either atrioventricular-sequential pacing or atrial-triggered
ventricular pacing in dual-chamber PMs. The basic pacing
rate of single-chamber devices was programmed to be above
the intrinsic heart rate. Preprogrammed sensitivity remained
unchanged for EMI testing. All PMs were interrogated
before the start of the test protocol, and all parameters were
recorded. The patients were advised to cross the AMDG at
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a normal walking speed back and forth. To simulate a
“worst-case scenario,” the patients were then asked to
remain at least 20 s within the AMDG and to perform a
360° torsion around the body axis. Thereafter, patients were
advised to place the chest side with the implanted PM
device as close as possible toward the transmitting side of
the AMDG. An external six-lead electrocardiogram (ECG)
was continuously recorded and evaluated with respect to
sensing abnormalities, such as atrial or ventricular oversens-
ing, or pacing abnormalities, such as a loss of capture or
pacing in the asynchronous mode. Interrogation of the PM
was repeated and analyzed for the occurrence of spontane-
ous reprogramming.
Test protocol for ICD. The test protocol for the patients
evaluated for EMI in the ICD group was carried out in a
similar fashion as that in the PM group. In contrast to the
PM patients, the ICD was programmed to maximal sensi-
tivity before being exposed to the AMDG field. The
minimal heart rate for the detection of arrhythmias was set
at 100 beats/min. The detection interval was programmed
to the shortest value available.
In all patients, ICD detection remained active while
delivery of therapies was programmed “off” (not applicable
to the Biotronik [Berlin, Germany] Belos VR/DR and St.
Jude/Ventritex [Sylmar, California] ICDs). Patients were
exposed to the AMDG, as described earlier. After AMDG
exposure and repeated interrogation of the ICD, Holter
monitoring data acquired by the ICD and all parameters
were printed out and analyzed for possible occurrence of
EMI.
Temporary suspension of therapies due to EMI (reed-
switch mechanism) was assessed by an acoustic signal
incorporated in Guidant/CPI (St. Paul, Minnesota) and
Medtronic (Minneapolis, Minnesota) devices or by interro-
gation for magnet reversion in St. Jude/Ventritex devices.
Statistical data. Data are presented as the mean  SD or
range.
RESULTS
PMs. A total of 203 PM systems were studied in 200
patients (3 patients with testing before and after exchange of
the pulse generator due to battery depletion). The mean age
of patients was 65  20 years (range 9 to 101 years), and 68
patients were female. Among the devices, there were 53
single-chamber PMs, 140 dual-chamber PMs, 9 VDD
systems with single-pass electrodes, and one biventricular
system for cardiac resynchronization therapy. The pacing
modes at the time of testing of interference were AAI(R)
(n  3), DDD(R) (n  111), two of which were in mode
switching due to atrial fibrillation at the time of testing,
DDDRV (n  1), DDI(R) (n  11), VDD (n  9), and
VVI(R) (n  68).
Atrial sensitivity was programmed at 0.6  0.3 mV
(range 0.1 to 2.0 mV) for bipolar leads (n 117) and 1.3 
0.8 mV (range 0.5 to 3.0 mV) for unipolar leads (n  16).
Ventricular sensitivity was programmed at 2.6  0.8 mV
(range 0.6 to 5.6 mV) for bipolar leads (n  95) and 3.8 
1.2 mV (range 1.3 to 8.0 mV) for unipolar leads (n  105).
The different PM and lead models are shown in Tables 1
and 2.
None of the following was observed in any of the 203
systems tested: atrial oversensing/inappropriate mode
switching, ventricular oversensing, atrial/ventricular loss of
capture, pacing in the magnet mode, or spontaneous repro-
gramming of the PM.
ICDs. A total of 151 ICD systems were studied in 148
patients (3 patients with testing for EMI before and after
exchange of the pulse generator due to battery depletion).
The mean age in the ICD group was 61  15 years (range
10 to 86 years), and 26 were female. Among the devices,
there were 101 single-chamber devices, 46 dual-chamber
devices, and 4 systems for cardiac resynchronization ther-
apy. Right ventricular sensing leads had a true bipolar
sensing configuration in 52 cases and integrated bipolar
sensing in 92 cases; the type of lead was unknown in 4
patients. Detailed information on the type of leads and ICD
are given in Tables 3 and 4. Maximal ICD sensitivity could
be programmed before the AMDG test in 142 (94.0%) of
151 ICD systems without T-wave oversensing or detection
of myopotentials.
In none of the 151 systems studied was ventricular over-
sensing resulting in inappropriate detection of (non)sus-
tained ventricular arrhythmias, spontaneous reprogramming
of the ICD, or temporary suspension of therapies observed
(test protocol not applicable to all systems in the last case).
DISCUSSION
Electromagnetic interference with PMs or ICDs is a rela-
tively rare but potentially serious adverse event in clinical
practice. Interactions with electronic article surveillance
systems and cellular telephone systems have been extensively
evaluated, showing a risk for both PM and ICD patients in
the case of acoustomagnetic article surveillance systems
(1–4) and for PM recipients (5–7,10–12) in the case of
cellular telephones. In contrast to potential interactions of
cellular telephones or electronic article surveillance systems
with implanted pacing devices that operate at much higher
pulse rates than the AMDG, data on interference caused by
AMDG are limited.
Regarding implanted PM systems, a study performed
more than a decade ago showed no interactions with the
AMDG (13). However, currently implanted PM systems
Abbreviations and Acronyms
AMDG  airport metal detector gate
ECG  electrocardiogram
EMI  electromagnetic interference
ICD  implantable cardioverter-defibrillator
PM  pacemaker
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significantly differ from those previously studied: multi-
programmable PMs have become standard, the percentage
of dual-chamber PMs has largely increased, and the atrial
sensing threshold is programmed to lower values (higher
sensitivity) in order to recognize atrial arrhythmias. To date,
ICD recipients have not been tested within the electromag-
netic field of an AMDG.
Theoretical and in vitro studies have shown that low-
frequency magnetic fields can interfere with PMs at a
magnetic flux density 16 to 42 T (14,15)—a value that
is also reached by the AMDG (16). However, the oscilla-
tion frequency of the AMDG’s electromagnetic field is
different from that used in the calculations, and PM filter
characteristics have not been considered. Therefore, the
reports mentioned previously may not be transferable to the
AMDG.
In none of the PM patients was atrial or ventricular
oversensing, loss of capture, pacing in the magnet mode, or
Table 1. Implantable Pacemakers Studied
Manufacturer
Single-Chamber
PM n
Dual-Chamber
PM n
Biotronik (n  14) Pikos 01 1 Actros D 1
Actros DR 1
Dromos DR 1
Eikos SLD* 4
Inos CLS 1
Kairos 3
Philos DR 1
Physios TC 01 1
ELA (n  21) Opus G 4621 1 Brio DR 212 1
Opus G 4624 2 Chorum 7234 1
Chorus RM 7034 1
Chorus II 6234 4
Chorus II 6244 3
Talent DR 213 8
Guidant/CPI (n  38) Discovery SR 1174 2 Insignia Plus DR 1298 1
Discovery SR 1175 1 Discovery DR 1274 1
Discovery II SR 1184 5 Discovery II DR 1284 1
Insignia Plus SR 1194 1 Pulsar Max DR 1270 1
Pulsar Max II SR 1180 1 Pulsar Max II DR 1280 13
Vigor SR 1130 1 Vigor DR 1230 6
Vigor SR 1135 2 Vigor DR 1235 2
Intermedics (n  27) Dart 292-05 1 Marathon DR 294-04 13
Dash 292-03 1 Stride 294-05 2
Marathon SR 292-09 4 Unity 292-07* 4
Marathon SR 292-09X 2
Medtronic (n  77) Kappa SR 401 8 AT 501 6
Kappa SR 706 1 Elite 7077 1
Legend 8417 1 InSync 8040† 1
Legend II 8424 2 Kappa DR 401 30
Minix 8341 2 Kappa DR 701 1
Prodigy SR 8160 1 Kappa DR 731 3
Sigma SR 203 1 Minuet 7108 1
Thera SR 8940 1 Prodigy DR 7860 1
Thera SR 8960i 4 Sigma DR 303 1
Sigma DR 353 1
Thera DR 7940 1
Thera DR 7950 1
Thera DR 7960i 7
Thera VDD 8968i* 1
St. Jude (n  22) Identity SR 5172 1 Affinity DR 5330 3
Integrity SR 5136 1 Entity DC 5226 1
Microny II 2525T 2 Identity DR 5370 4
Prolog 688 1 Integrity AFx DR 5346 1
Regency SR 2400 1 Integrity DR 5336 4
Paragon 2010 1
Synchrony III 2028 2
Vitatron (n  4) Diamond 3 1 Clarity 860 1
Prevent AF 1
Selection AF 2.0 1
*VDD pacemaker with single-pass electrode. †Biventricular pacing system.
PM  pacemaker.
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spontaneous reprogramming observed. This is in accordance
with the findings of Copperman et al. (13). In none of our
ICD patients did inappropriate tachyarrhythmia detection
occur, despite programming of the highest sensitivity, short-
est detection interval, and detection rates lower than those
usually applied. Spontaneous reprogramming was not ob-
served.
Pacemaker sensitivity for the EMI test was unchanged
when compared with the individually optimized program-
ming obtained during the preceding follow-ups, thus avoid-
ing oversensing. Programming of increased PM sensitivity
for the AMDG test would have introduced difficulties in
determination of the source of interference in the case of
PM inhibition (i.e., EMI vs. intermittent myopotential
oversensing). To obtain an additional safety margin for the
evaluation of possible interference, the ICDs were pro-
grammed to maximal sensitivity.
In ICD patients, evaluation of possible interference was
mainly based on ICD Holter monitoring data acquired after
passing the AMDG. This enables sensitive detection of
even short-lasting episodes of interference and interpreta-
tion of stored electrograms.
Study limitations. Interpretation of the six-lead ECG in
PM patients may be difficult in some instances, with respect
Table 2. Implantable Pacemaker Leads Studied
Manufacturer Ventricular Lead Model n Atrial Lead Model n
Biotronik Polyrox PX 60-UP 2 Elox 53-BP 1
SD 60-BP 1 Polyrox PX 53-BP 1
SL 60/13 UP* 1 Polyrox PX 60-BP 1
SL 60/15 UP* 4 SL 60/15 UP* 4
Synox SX 60-BP 1 Y 53-BP 2
TIR 60-BP 3 Y 60-BP 1
TIR 60-UP 1
Cordis Ball 4
ELA Stela BT 46 2
T 83 F 1
Guidant Selute Picotip MFGR4032 1
Intermedics 425-13* 3 425-13* 2
425-16* 1 425-16* 1
430-07 1
Medtronic 4057M 1 4058M 3
4058M 3 4557M 1
6901 1 5071 1
6917 1 6917 1
Attain LV 2187† 1 6957 1
CapSure 4003 1 CapSure Epi 4968 1
CapSure 5032* 1 CapSure SP 4023 1
CapSure SP 4023 47 CapSure SP 4524 4
CapSure SP 4024 21 CapSureFix 4068 12
Capsure SP Novus 4092 54 CapSureFix 4568 11
CapSureFix 4068 2 CapSureFix Novus 5072 1
Target Tip 4011 1 CapSureFix Novus 5076 5
Osypka PY 62 1 PJ 66 C 1
QT 67 T 1 PU II 1
QT 67 TN 1 PY 61 3
VY 61 1 PY 67 V 1
PY 87 C 1
PY III 167 C 1
VY 61 1
Sorin S200 1
S 80 T 1
St. Jude 412M/85 2 Membrane EX 1447T 1
424K/60 2 Tendril DX 1388T 62
424M/60 3 Tendril DX 1488T 1
588M 1
1085K/60 2
Membrane 1403K 2
Membrane E 1450T 2
Membrane EX 1470T 4
Membrane EX 1472K 1
Vasco Tip cc 1
Vitatron Excellence 1
Unknown 10 5
Leads active for sensing and/or pacing are listed only. *Single-pass electrode. †Left ventricular lead.
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to evaluation of absolute correct sensing and pacing behavior.
Some special functions of the PM (e.g., automatically
adjusted refractory periods, sensing thresholds, pacing out-
puts) cannot be judged solely by the surface ECG. Short-
term atrial oversensing exclusively presenting within refrac-
tory periods cannot be precluded from the surface ECG. In
these circumstances, continuous marker recordings would
help to analyze PM behavior. Recording of the marker
ECG in our study was abandoned after a pilot phase, for
practical reasons such as frequent loss of telemetry in older
Table 3. Implantable Cardioverter-Defibrillators Studied
Manufacturer
Single-Chamber
ICD n
Dual-Chamber
ICD n
Biotronik (n  10) Belos VR 2 Phylax AV 2
Microphylax 4
Microphylax Plus 1
Phylax 06 1
Guidant/CPI (n  58) Mini I 1 Contak CD 2
Mini III 6 Contak Renewal 2
Mini IV 6 Prizm DR 1 3
Mini IV HE 1 Prizm DR 2 8
Prizm VR 1 4 Ventak AV DR I 1
Prizm VR 2 16 Ventak AV DR II 3
Prizm VR 2 HE 1 Ventak AV DR III 4
Medtronic (n  71) GEM 7227 17 GEM DR 7271 8
GEM II VR 7229 7 GEM II DR 7273 1
GEM III VR 7231 11 GEM III DR 7275 5
Jewel Plus 7220 2 GEM III AT 7276 1
Micro Jewel 7221 3 Jewel AF 7250 4
Micro Jewel II 7223 8 Marquis DR 7274 2
Marquis VR 7230 2
St. Jude/Ventritex (n  12) Atlas VR V-199 1 Atlas DR V-240 1
Cadet V 115 AC 1 Photon DR V-230HV 3
Contour V 145 AC 2
Profile V 186 F 1
Photon V 230 HV 3
ICD  implantable cardioverter-defibrillator.
Table 4. Leads Used in Patients With an Implantable Cardioverter-Defibrillator
Manufacturer Ventricular Lead n Atrial Lead n
Biotronik Kainox RV 75 2 YP53-BP 1
Kainox SL 75/18 1
Kainox SL 75/16 2
SPS 75 3
Guidant/CPI Easytrack 4512† 2
Endotak 0072 3
Endotak DSP 0095 2
Endotak DSP 0125 10
Endurance 0135 2
Endurance 0145 14
Reliance 0147 1
Reliance 0148 22
Intermedics 497-19 1
Medtronic Capsure SP Novus 4092* 1 6940 2
Sprint 6932 19 Capsure SP 4024 1
Sprint 6942 15
Sprint 6943 2
Sprint 6945 3
Sprint Quattro 6944 21
Transvene 6936 9
Transvene 6966 2
St. Jude/Ventritex SPL SP 01 2 Tendril DX 1388T 43
SPL SP 02 1 Tendril DX 1488T 1
TVL RV 02 4
TVL RV 06 2
Lead unknown 4 2
Leads active for sensing are listed only. *Additional pace/sense lead. †Left ventricular pacing and sensing lead.
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PM systems when following the patient through the
AMDG, as well as the electromagnetic field disturbing
telemetry (12). Thus, minor sensing abnormalities that are
undetectable by surface ECG recordings cannot be ruled out
completely.
Conclusions. In vivo testing of 203 PM and 151 ICD
systems revealed no EMI with a standard AMDG. Con-
sidering a period of just a few seconds within the electro-
magnetic field for routine airport security controls, clinically
relevant interactions with PMs or ICDs seem to be unlikely.
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